Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.

Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, Mathis CA, Price JC, Klunk WE.

Alzheimers Dement. 2012 Nov;8(6):496-501. doi: 10.1016/j.jalz.2011.09.229.

2.

The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B.

Lao PJ, Betthauser TJ, Hillmer AT, Price JC, Klunk WE, Mihaila I, Higgins AT, Bulova PD, Hartley SL, Hardison R, Tumuluru RV, Murali D, Mathis CA, Cohen AD, Barnhart TE, Devenny DA, Mailick MR, Johnson SC, Handen BL, Christian BT.

Alzheimers Dement. 2016 Apr;12(4):380-90. doi: 10.1016/j.jalz.2015.05.013.

PMID:
26079411
3.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W.

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112.

4.

Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility.

Landt J, D'Abrera JC, Holland AJ, Aigbirhio FI, Fryer TD, Canales R, Hong YT, Menon DK, Baron JC, Zaman SH.

Arch Neurol. 2011 Jul;68(7):890-6. doi: 10.1001/archneurol.2011.36.

PMID:
21403005
5.

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA.

J Neurosci. 2005 Nov 16;25(46):10598-606.

6.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group..

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125.

PMID:
22628162
7.

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.

Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement. 2011 Mar;7(2):133-41. doi: 10.1016/j.jalz.2010.08.230.

8.

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.

Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE.

J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6. doi: 10.1136/jnnp-2012-302548.

9.

Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.

Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, Pimlott S, Hutchinson PJ, Tavares A, Canales R, Mathis CA, Klunk WE, Aigbirhio FI, Coles JP, Baron JC, Pickard JD, Fryer TD, Stewart W, Menon DK.

JAMA Neurol. 2014 Jan;71(1):23-31. doi: 10.1001/jamaneurol.2013.4847.

10.

Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome.

Hartley SL, Handen BL, Devenny DA, Hardison R, Mihaila I, Price JC, Cohen AD, Klunk WE, Mailick MR, Johnson SC, Christian BT.

Brain. 2014 Sep;137(Pt 9):2556-63. doi: 10.1093/brain/awu173.

11.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.

Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016.

12.

Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers.

Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN.

Brain. 2011 Jan;134(Pt 1):293-300. doi: 10.1093/brain/awq310.

PMID:
21084313
13.

Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches.

Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, Nebes RD, Saxton JA, Snitz B, Dekosky S, Williamson J, Lopez OL, Price JC, Mathis CA, Klunk WE.

Neuroimage. 2013 May 1;71:207-15. doi: 10.1016/j.neuroimage.2013.01.015.

14.

Low amyloid-β deposition correlates with high education in cognitively normal older adults: a pilot study.

Yasuno F, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A, Yamamoto A, Matsuoka K, Kosaka J, Kudo T, Iida H, Kishimoto T.

Int J Geriatr Psychiatry. 2015 Sep;30(9):919-26. doi: 10.1002/gps.4235.

PMID:
25425062
15.

Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B.

Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, Tsopelas ND, Lopresti BJ, Reynolds CF 3rd, DeKosky ST, Meltzer CC.

Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):261-8. doi: 10.1097/WAD.0b013e31816c92bf.

16.

A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain.

Matveev SV, Spielmann HP, Metts BM, Chen J, Onono F, Zhu H, Scheff SW, Walker LC, LeVine H 3rd.

J Neurochem. 2014 Nov;131(3):356-68. doi: 10.1111/jnc.12815.

17.

Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, Mintun MA; Alzheimer’s Disease Neuroimaging Initiative..

J Nucl Med. 2013 Jan;54(1):70-7. doi: 10.2967/jnumed.112.109009.

18.

In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, Rosario BL, Lopresti BJ, Saxton JA, Aizenstein HJ, McDade EM, Kamboh MI, DeKosky ST, Lopez OL.

Ann Neurol. 2013 Jun;73(6):751-61. doi: 10.1002/ana.23797.

19.

Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.

Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, Lah JJ, Ghiso JA, LeVine H 3rd, Walker LC.

Acta Neuropathol. 2010 Feb;119(2):221-33. doi: 10.1007/s00401-009-0583-3.

20.

Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.

Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ.

Arch Neurol. 2012 Feb;69(2):223-9. doi: 10.1001/archneurol.2011.666.

Items per page

Supplemental Content

Support Center